← Back

Wire · regulatory

FDA moves to yank Salerno's liquid cholesterol drug approval on missing reports

Published

18 November 2026

Topic

regulatory

◆ Sectors

Drug Discovery

◆ Geography

United States

◆ Source

Read at fiercepharma.com →

◆ Verified

Fusion42 · 18 November 2026 · Fusion42 review

The FDA is moving to withdraw approval for Salerno Pharmaceuticals' FloLipid cholesterol drug due to the company's failure to submit required annual reports and respond to FDA requests. Salerno has until December 18, 2026, to request a hearing to defend the drug's approval.

This Wire brief sits within Fusion42's coverage of Drug Discovery, and 3 sources have reported it.

◆ ◆ The Wire takeaway

You must elevate compliance tracking as FDA enforcement can revoke product approval quickly, blocking market access. Missing regulatory steps puts your drug at immediate risk of withdrawal, triggering urgent defence or exit moves.

◆ Coverage

3 sources · 18 Nov 2026

◆ Related on Wire

◆ Topics

Drug DiscoveryFDAdrug-approvalregulatory-compliancepharmaceuticalscholesterol